Table IV.
Univariate and multivariate analyses of factors associated with the progression-free survival (patients who received previous gefitinib treatment).
| Variable | No. of patients | Univariate hazard ratio (95% CI) | P-value | Multivariate hazard ratio (95% CI) | P-value |
|---|---|---|---|---|---|
| Gender | 0.235 | ||||
| Male | 24 | 1.342 (0.825–2.183) | |||
| Female | 67 | 1 | |||
| ECOG performance status | 0.587 | ||||
| 3–4 | 9 | 1.226 (0.588–2.556) | |||
| 0–2 | 82 | 1 | |||
| Smoking history | 0.615 | ||||
| Current or former | 31 | 1.123 (0.714–1.766) | |||
| Never | 60 | 1 | |||
| Histological type | 0.035 | 0.809 | |||
| Non-adenocarcinoma | 2 | 4.784 (1.116–20.408) | 3.74 (0.850–16.393) | ||
| Adenocarcinoma | 89 | 1 | |||
| Prior regimens | 0.125 | ||||
| >2 | 77 | 1.690 (0.864–3.303) | |||
| 0–1 | 14 | 1 | |||
| EGFR status | 0.388 | ||||
| Wild type or unknown | 41 | 1.210 (0.784–1.865) | |||
| Mutation | 50 | 1 | |||
| Response of gefitinib | 0.0139 | 0.249 | |||
| PD | 12 | 2.271 (1.181–4.365) | 2.141 (1.101–4.164) | ||
| CR-SD | 79 | 1 | |||
| Duration of gefitinib treatment | 0.6125 | ||||
| <12 | 58 | 1.122 (0.718–1.754) | |||
| >12 | 33 | 1 | |||
| Interval between gefitinib and erlotinib treatment | 0.429 | ||||
| <12 | 57 | 1.197 (0.766–1.871) | |||
| >12 | 34 | 1 |
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PD, progressive disease; CR, complete response; SD, stable disease.